Investment Analysts’ Weekly Ratings Changes for Pfizer (PFE)

Pfizer (NYSE: PFE) has recently received a number of price target changes and ratings updates:

• 10/13/2026 – Pfizer had its “buy” rating reaffirmed by Guggenheim.
• 10/10/2026 – Pfizer was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/9/2026 – Pfizer had its price target raised by JPMorgan Chase & Co. from $28.00 to $30.00. They now have a “neutral” rating on the stock.
• 10/8/2026 – Pfizer had its price target raised by Cantor Fitzgerald from $27.00 to $28.00. They now have a “neutral” rating on the stock.
• 10/6/2026 – Pfizer had its price target raised by Scotiabank from $30.00 to $33.00. They now have an “outperform” rating on the stock.
• 9/13/2026 – Pfizer was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/10/2026 – Pfizer had its price target raised by HSBC Holdings plc from $28.00 to $30.00. They now have a “hold” rating on the stock.
• 9/5/2026 – Pfizer was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/31/2026 – Pfizer was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/17/2026 – Pfizer was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.8%. Pfizer’s payout ratio is currently 226.32%.

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.